Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25721686 | 1.00 | CYP2D6 (0.41) | CYP2D6CTSKCTSSHDAC3HDAC1 | |
| SCHEMBL21065977 | 1.00 | CYP2D6 (0.41) | CYP2D6CTSKCTSSHDAC3HDAC1 | |
| SCHEMBL14350539 | 1.00 | CYP2D6 (0.41) | CYP2D6CTSKCTSSHDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL5656221 | 0.99 | CYP2D6 (0.40) | CYP2D6CTSKCTSSHDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL21066070 | 0.99 | CYP2D6 (0.40) | CYP2D6CTSKCTSSHDAC3HDAC1 | |
| SCHEMBL5565359 | 0.86 | CYP2D6 (0.51) | CYP2D6CTSKCTSSHDAC3HDAC1 | |
| SCHEMBL14350548 | 0.86 | CYP2D6 (0.51) | CYP2D6CTSKCTSSHDAC3HDAC1 | |
| SCHEMBL15044399 | 0.86 | TSHR (0.31) | — | |
| Hydrochloric Acid SCHEMBL5565353 | 0.85 | CYP2D6 (0.50) | CYP2D6CTSKCTSSHDAC3HDAC1 | |
| SCHEMBL24065096 | 0.83 | GAA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11633500-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | AGENSYS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230071763-A1 | AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| EP-4087855-A1 | AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF | CytomX Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-114981287-A | Auristatin-related compounds, conjugated auristatin compounds, and methods of use thereof | 西托姆克斯治疗公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11236076-B2 | Reaction medium containing water-surfactant mixture | NOVARTIS AG (CH) | 2022-02-01 | — | — | US | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012123423-A1 | N-CARBOXYALKYL-AURISTATINS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012041805-A1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-20120078028-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEAGEN INC. | 2012-03-29 | — | — | US | disclosed |
| WO-2011154359-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-15 | — | — | WO | disclosed |
| US-20110217321-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20100330107-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7423116-B2 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330107-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | CD2BP2, IGSF11, PA2G4 | CYP2D6 2524/4885CTSK 4272/4885CTSS 4407/4885 |
| US-20110217321-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | CD2BP2, IGSF11, EPB41L2 | CYP2D6 3648/4885CTSK 3863/4885CTSS 4066/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | CYP2D6 990/4885CTSK 1361/4885CTSS 1652/4885 |
| US-20230071763-A1 | AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF | AURKC, AURKA, AURKB | CYP2D6 4787/4885CTSK 954/4885CTSS 1433/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | CYP2D6 757/4885CTSK 3323/4885CTSS 3232/4885 |
| US-11236076-B2 | Reaction medium containing water-surfactant mixture | SRR, PHOSPHO1, NAPEPLD | CYP2D6 165/4885CTSK 826/4885CTSS 749/4885 |
| US-11633500-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | SIGLEC7, FUT7, SLC17A5 | CYP2D6 414/4885CTSK 2186/4885CTSS 1740/4885 |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, PA2G4 | CYP2D6 2347/4885CTSK 3811/4885CTSS 3794/4885 |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | ALDH7A1, BCAT1, BCAT2 | CYP2D6 285/4885CTSK 2415/4885CTSS 1951/4885 |
| US-20120078028-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, ADCK5 | CYP2D6 2452/4885CTSK 3844/4885CTSS 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.